000008338 001__ 8338
000008338 005__ 20240408091644.0
000008338 0247_ $$2DOI$$a10.6083/bc386j919
000008338 037__ $$aIR
000008338 041__ $$aeng
000008338 245__ $$aFluorescence imaging technologies for in situ measurement of drug target engagement and cell signaling pathway reprogramming
000008338 260__ $$bOregon Health and Science University
000008338 269__ $$a2020
000008338 336__ $$aAbstract
000008338 520__ $$aSuccessful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this interaction network and identify therapeutic targets. Tyrosine kinase inhibitors (TKI) are a class of molecularly targeted therapeutics seeking to inhibit signaling pathways critical to sustaining prolifierative signaling, resisting cell death, and the other hallmarks of cancer. While tumors may initially respond to TKI therapy, disease progression is inevitable due to mechanisms of acquired resistance largely involving cellular signaling pathway reprogramming. With the ultimate goal of improved molecularly targeted therapeutic efficacy, our group has developed intracellular paired agent imaging (iPAI) to quantify drug target intereactions and oligonucleotide conjugated antibody (Ab-oligo) cyclic immunofluorescence (cycIF) imaging to characterize perturbed signaling pathways in response to therapy.
000008338 540__ $$fCC BY
000008338 542__ $$fIn copyright - joint owners
000008338 650__ $$aFluorescence$$019121
000008338 650__ $$aTyrosine Protein Kinase Inhibitors$$013842
000008338 6531_ $$acancer
000008338 6531_ $$acyclic immunofluorescence
000008338 6531_ $$aintracellular paired agent imaging
000008338 6531_ $$aoligonucleotide conjugated antibody
000008338 6531_ $$afluorescent tagging
000008338 691__ $$aSchool of Medicine$$041369
000008338 692__ $$aDepartment of Biomedical Engineering$$041397
000008338 7001_ $$aMcMahon, Nathan$$uOregon Health and Science University$$041354
000008338 7001_ $$aSolanki, Allison$$uOregon Health and Science University$$041354
000008338 7001_ $$aJones, Jocelyn$$uOregon Health and Science University$$041354
000008338 7001_ $$aWang, Lei$$uOregon Health and Science University$$041354
000008338 7001_ $$aTichauer, Kenneth$$uOregon Health and Science University$$041354
000008338 7001_ $$aSamkoe, Kimberly$$uOregon Health and Science University$$041354
000008338 7001_ $$aGibbs, Summer L.$$uOregon Health and Science University$$041354
000008338 711__ $$aResearch Week$$uOregon Health and Science University$$d2020
000008338 8564_ $$9c4ed8d8d-317c-4cf9-9968-abcc3b6c8f8e$$s45447$$uhttps://digitalcollections.ohsu.edu/record/8338/files/ResearchWeek.2020.McMahon.Nathan.pdf
000008338 905__ $$a/rest/prod/bc/38/6j/91/bc386j919
000008338 980__ $$aResearch Week